aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · Real-Time Price · USD
0.2880
-0.0061 (-2.07%)
Oct 2, 2026, 12:41 PM EDT - Market open
aTyr Pharma Revenue
In the year 2025, aTyr Pharma had annual revenue of $190.00K, down -19.15%.
Revenue (ttm)
$190.00K
Revenue Growth
-19.15%
P/S Ratio
151.83
Revenue / Employee
$3,167
Employees
60
Market Cap
28.25M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 190.00K | -45.00K | -19.15% |
| Dec 31, 2024 | 235.00K | -118.00K | -33.43% |
| Dec 31, 2023 | 353.00K | -10.03M | -96.60% |
| Dec 31, 2022 | 10.39M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 10.46M | 10.03M | 2,377.49% |
| Dec 31, 2019 | 422.00K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
ATYR News
- 3 days ago - Two stock picks from a money manager who expects small caps to roar in 2027 - Market Watch
- 8 days ago - Why is aTyr Pharma Stock (ATYR) Down 7% Today? - TipRanks
- 8 days ago - aTyr Pharma announces alignment with FDA on Phase 3 study of efzofitimod - TheFly
- 8 days ago - aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis - GlobeNewsWire
- 21 days ago - aTyr Pharma Proxy statement: Proxy filing - Filings
- 4 weeks ago - aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis - GlobeNewsWire
- 4 weeks ago - aTyr Pharma Proxy statement: Proxy filing - Filings
- 6 weeks ago - Ethos to Present at the Goldman Sachs Communacopia + Technology Conference - GlobeNewsWire